Global Advanced Urotheilal carcinoma Pipeline Insight Report 2021 Featuring Rogaratininb (Bayer) & Sitravatinib (Mirati Therapeutics) –

DUBLIN–(BUSINESS WIRE)–The “Advanced Urotheilal carcinoma – Pipeline Insight, 2021” drug pipelines has been added to’s offering.

This “Advanced Urothelial Carcinoma – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Advanced Urothelial Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and non clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Urothelial Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Urothelial Carcinoma.

Advanced Urothelial Carcinoma Emerging Drugs Chapters

This segment of the Advanced Urothelial Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced Urothelial Carcinoma Emerging Drugs

  • Rogaratininb: Bayer

Bayer’s drug candidate rogaratinib is in the phase II/III stage of the drug development process. The drug molecule is an investigational fibroblast growth factor receptor (FGFR) inhibitor that has shown potential in inhibiting the pathway in preclinical studies. The drug molecule has shown to be prevent both ligand-dependent and independent FGFR activation.

  • Sitravatinib: Mirati Therapeutics, Inc

Mirati Therapeutics’s drug candidate Sitravatinib, is a multi targeted tyrosine kinase inhibitor which is being tested for NSCLC as well as advanced urothelial carcinoma. For the latter indication, the drug is being evaluated in phase II trial where its effect is being tested as an orally administered drug to be given in combination with nivolumab.

Advanced Urothelial Carcinoma: Therapeutic Assessment

This segment of the report provides insights about the different Advanced Urothelial Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Advanced Urothelial Carcinoma

There are approx. 4+ key companies which are developing the therapies for Advanced Urothelial Carcinoma. The companies which have their Advanced Urothelial Carcinoma drug candidates in the most advanced stage, i.e. phase II include, Bayer.

The report covers around 10+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Advanced Urothelial Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intramuscular
  • Subcutaneous
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Advanced Urothelial Carcinoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Urothelial Carcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Urothelial Carcinoma drugs.

Advanced Urothelial Carcinoma Report Insights

  • Advanced Urothelial Carcinoma Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Advanced Urothelial Carcinoma Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Advanced Urothelial Carcinoma drugs?
  • How many Advanced Urothelial Carcinoma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Urothelial Carcinoma?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Advanced Urothelial Carcinoma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Advanced Urothelial Carcinoma and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Bayer
  • Mirati Therapeutics

Key Products

  • Rogaratininb
  • Sitravatinib

For more information about this drug pipelines report visit


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900